nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.07.2013 | Preclinical Study

Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells

verfasst von: Tatjana Kaiser, Ingrid Teufel, Konstanze Geiger, Yvonne Vater, Wilhelm K. Aicher, Gerd Klein, Tanja Fehm

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Bisphosphonates (BPs) are in clinical use for the treatment of breast cancer patients with bone metastases. Their anti-resorptive effect is mainly explained by inhibition of osteoclast activity, but recent evidence also points to a direct action of BPs on bone-forming osteoblasts. However, the mechanisms how BPs influence osteoblasts and their interactions with breast cancer cells are still poorly characterized. Human osteoblasts isolated from bone specimens were characterized in depth by their expression of osteogenic marker genes. The influence of the nitrogen-containing BPs zoledronate (Zol), ibandronate (Iban), and pamidronate (Pam) on molecular and cellular functions of osteoblasts was assessed focusing on cell proliferation and viability, apoptosis, cytokine secretion, and osteogenic-associated genes. Furthermore, effects of BPs on osteoblast–breast tumor cell interactions were examined in an established in vitro model system. The BPs Zol and Pam inhibited cell viability of osteoblasts. This effect was mediated by an induction of caspase-dependent apoptosis in osteoblasts. By interfering with the mevalonate pathway, Zol also reduces the proliferation of osteoblasts. The expression of phenotypic markers of osteogenic differentiation was altered by Zol and Pam. In addition, both BPs strongly influenced the secretion of the chemokine CCL2 by osteoblasts. Breast cancer cells also responded to Zol and Pam with a reduced cell adhesion to osteoblast-derived extracellular matrix molecules and with a decreased migration in response to osteoblast-secreted factors. BPs revealed prominent effects on human osteoblasts. Zol and Pam as the most potent BPs affected not only the expression of osteogenic markers, osteoblast viability, and proliferation but also important osteoblast–tumor cell interactions. Changing the osteoblast metabolism by BPs modulates migration and adhesion of breast cancer cells as well.

Nur mit Berechtigung zugänglich

Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359(26):2814–2823PubMedCrossRef

Guise TA, Brufsky A, Coleman RE (2010) Understanding and optimizing bone health in breast cancer. Curr Med Res Opin 26:3–20PubMedCrossRef

Gnant M, Hadji P (2010) Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res 12(6):216PubMedCrossRef

Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97(3 Suppl):834–839PubMedCrossRef

Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090PubMedCrossRef

Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH et al (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16(12):3890–3899PubMed

Mundy GR, Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339(6):398–400PubMedCrossRef

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759PubMedCrossRef

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13(4):581–589PubMedCrossRef

10.

Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91(5):2004–2011PubMedCrossRef

11.

Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137(6):2324–2333PubMedCrossRef

12.

Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25(6):539–546PubMed

13.

Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD (2009) Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 37(2):407–416PubMedCrossRef

14.

Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP (2010) Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28(6):873–879PubMed

15.

Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291(3):680–686PubMedCrossRef

16.

Frediani B, Spreafico A, Capperucci C, Chellini F, Gambera D, Ferrata P, Baldi F, Falsetti P, Santucci A, Bocchi L et al (2004) Long-term effects of neridronate on human osteoblastic cell cultures. Bone 35(4):859–869PubMedCrossRef

17.

Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34(1):112–123PubMedCrossRef

18.

Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P et al (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23(1):6–16PubMedCrossRef

19.

Garcia-Moreno C, Serrano S, Nacher M, Farre M, Diez A, Marinoso ML, Carbonell J, Mellibovsky L, Nogues X, Ballester J et al (1998) Effect of alendronate on cultured normal human osteoblasts. Bone 22(3):233–239PubMedCrossRef

20.

Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B (2007) The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80(4):769–775PubMed

21.

Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60(21):6001–6007PubMed

22.

Senaratne SG, Colston KW (2002) Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4(1):18–23PubMedCrossRef

23.

Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949–2954PubMed

24.

Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459–1468PubMedCrossRef

25.

Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287(1):109–116PubMedCrossRef

26.

Dedes PG, Gialeli C, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, Tzanakakis GN, Karamanos NK (2012) Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 1820(12):1926–1939PubMedCrossRef

27.

Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P et al (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36(8):615–620PubMedCrossRef

28.

Burger JA, Kipps TJ (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5):1761–1767PubMedCrossRef

29.

Roodman DG (2003) Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 97(3 Suppl):733–738CrossRef

30.

Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Anal Biochem 159(1):109–113PubMedCrossRef

31.

Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S, Lammers R, Wesselborg S, Stork B (2009) The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer 125(4):932–941PubMedCrossRef

32.

Masuda T, Deng X, Tamai R (2009) Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation. Int Immunopharmacol 9(9):1115–1121PubMedCrossRef

33.

Schüler Y, Lee-Thedieck C, Geiger K, Kaiser T, Ino Y, Aicher WK, Klein G (2012) Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells. Int J Cancer 130(2):288–299PubMedCrossRef

34.

Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465–473PubMedCrossRef

35.

Coleman ML, Olson MF (2002) Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ 9(5):493–504PubMedCrossRef

36.

Conti P, DiGioacchino M (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc 22(3):133–137PubMedCrossRef

37.

Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O’Brien T, Kerin MJ (2009) Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124(2):326–332PubMedCrossRef

38.

Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC (2007) Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 282(45):33098–33106PubMedCrossRef

39.

Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8(7):578–586PubMedCrossRef

40.

Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, Zhang J (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66(12):1311–1318PubMedCrossRef

41.

Loberg RD, Tantivejkul K, Craig M, Neeley CK, Pienta KJ (2007) PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem 101(5):1292–1300PubMedCrossRef

42.

Kinder M, Chislock E, Bussard KM, Shuman L, Mastro AM (2008) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314(1):173–183PubMedCrossRef

43.

Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L (2007) EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 282(37):26656–26664PubMedCrossRef

44.

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222–225PubMedCrossRef

45.

Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D, Teti A (1999) Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 81(3):395–403PubMedCrossRef

46.

Gallo M, De Luca A, Lamura L, Normanno N (2012) Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 23(3):597–604PubMedCrossRef

47.

Walter M, Liang S, Ghosh S, Hornsby PJ, Li R (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28(30):2745–2755PubMedCrossRef

48.

Knerr K, Ackermann K, Neidhart T, Pyerin W (2004) Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int J Cancer 111(1):152–159PubMedCrossRef

49.

Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM (2006) Chemokine (C–C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66(14):7176–7184PubMedCrossRef

Titel: Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells
verfasst von: Tatjana Kaiser
Ingrid Teufel
Konstanze Geiger
Yvonne Vater
Wilhelm K. Aicher
Gerd Klein
Tanja Fehm
Publikationsdatum: 01.07.2013
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2613-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa

Ultrasound-guided fine-needle aspiration of suspicious nodes in breast cancer patients; selecting patients with extensive nodal involvement

Weight, inflammation, cancer-related symptoms and health-related quality of life among breast cancer survivors

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations

Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie